Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 6/20 | 1.00 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 1/20 | 1.00 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 3/20 | 0.72 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.72 |
| ▸ | VRK2 | Q86Y07 | 1/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | USP7 | Q93009 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mmv-048 SCHEMBL29413286 | 1.00 | KCNH2 (1.00) | KCNH2MAP4K4MINK1PIK3CAPI4KB | |
| Mmv-048 SCHEMBL29575216 | 1.00 | KCNH2 (1.00) | KCNH2MAP4K4MINK1PIK3CAPI4KB | |
| SCHEMBL2225148 | 0.88 | MAP4K4 (0.79) | KCNH2MAP4K4MINK1PIK3CAPI4KB | |
| SCHEMBL2225558 | 0.88 | KCNH2 (0.78) | KCNH2MAP4K4MINK1PIK3CAPI4KB | |
| SCHEMBL2227291 | 0.87 | MAP4K4 (0.86) | KCNH2MAP4K4MINK1PIK3CAPI4KB | |
| SCHEMBL2227172 | 0.85 | MAP4K4 (0.74) | KCNH2MAP4K4MINK1PIK3CAPI4KB | |
| SCHEMBL2226484 | 0.85 | MAP4K4 (0.78) | KCNH2MAP4K4MINK1PIK3CAPI4KB | |
| SCHEMBL2227047 | 0.84 | MAP4K4 (0.72) | KCNH2MAP4K4MINK1PIK3CAPI4KB | |
| SCHEMBL2223417 | 0.84 | MAP4K4 (0.76) | KCNH2MAP4K4MINK1PIK3CAPI4KB | |
| SCHEMBL2225202 | 0.84 | FYN (1.00) | KCNH2MAP4K4MINK1PIK3CAPI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4077308-B1 | ANTI-MALARIAL AGENTS | UNIV TEXAS (US) | 2024-02-14 | — | — | EP | claimed |
| EP-3906225-B1 | PANTOTHENAMIDE ANALOGUES | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2023-07-05 | — | — | EP | claimed |
| CN-115380027-A | Novel antimalarial agents | 肯塔基大学研究基金会 | 2022-11-22 | — | — | CN | claimed |
| EP-2526090-B1 | NEW ANTI-MALARIAL AGENTS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2015-08-19 | — | — | EP | claimed |
| US-9024033-B2 | Anti-malarial agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2015-05-05 | — | — | US | claimed |
| CN-102812006-A | New anti-malarial agents | MEDICINES FOR MALARIA VENTURE MMV | 2012-12-05 | — | — | CN | claimed |
| US-20120295905-A1 | NEW ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2012-11-22 | — | — | US | claimed |
| WO-2011086531-A2 | NEW ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2011-07-21 | — | — | WO | claimed |
| CN-115380027-A | Novel antimalarial agents | 肯塔基大学研究基金会 | 2022-11-22 | — | — | CN | disclosed |
| CN-114829351-A | Novel antimalarial agents containing heterocyclic compounds | 卫材R&D管理有限公司 | 2022-07-29 | — | — | CN | disclosed |
| EP-2526090-B1 | NEW ANTI-MALARIAL AGENTS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2015-08-19 | — | — | EP | disclosed |
| EP-2526090-B1 | NEW ANTI-MALARIAL AGENTS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-9024033-B2 | Anti-malarial agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2015-05-05 | — | — | US | disclosed |
| US-9024033-B2 | Anti-malarial agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2015-05-05 | — | — | US | disclosed |
| CN-102812006-A | New anti-malarial agents | MEDICINES FOR MALARIA VENTURE MMV | 2012-12-05 | — | — | CN | disclosed |
| US-20120295905-A1 | NEW ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2012-11-22 | — | — | US | disclosed |
| WO-2011086531-A2 | NEW ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295905-A1 | NEW ANTI-MALARIAL AGENTS | QDPR, DHFR, ITPA | KCNH2 1101/4885MAP4K4 1556/4885MINK1 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.